SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance

U.S. Markets open in 9 hrs 25 mins

Sanofi (SNY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
39.77-0.75 (-1.85%)
At close: 4:02 PM EST
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close40.52
Bid39.72 x 200
Ask39.82 x 200
Day's Range39.54 - 39.92
52 Week Range36.81 - 44.50
Avg. Volume2,605,217
Market Cap102.63B
PE Ratio (TTM)23.12
Earnings DateN/A
Dividend & Yield1.66 (4.07%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Biotechs 'Round-Trip' Trump-Inspired Rally; FDA Appointment Key
    Investor's Business Daily7 hours ago

    Biotechs 'Round-Trip' Trump-Inspired Rally; FDA Appointment Key

    Biotech stocks have nearly "round-tripped" their Donald Trump-inspired rally.

  • Investopedia9 hours ago

    EU Regulators Will Review Regeneron's Eczema Drug

    Regeneron and Sanofi’s eczema drug makes progress toward being marketed in Europe.

  • Reuters22 hours ago

    EU regulator accepts Sanofi/Regeneron's Dupixent product for review

    The European Medicines Agency (EMA), the European Union's health regulator, has accepted for review the Dupixent product being developed by drugmakers Sanofi and Regeneron, the companies said on Thursday. Dupixent is aimed at adults with eczema or moderate-to-severe atopic dermatitis (AD), who are candidates for systemic therapy. If cleared by regulators, Dupixent would be the first approved systemic treatment for eczema, which in severe cases produces infection-prone rashes and a constant itch as bad as poison ivy.